2023 ESC Guidelines for the management of cardiomyopathiesElena Arbelo, Ulf Landmesser, Ruxandra Jurcuţ et al.|European Heart Journal|2023Cited by 2.3k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Artur Oręziak et al.|The Lancet|2020Cited by 1.2k
Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic CardiomyopathiesMartín Ortiz-Genga, Lorenzo Monserrat, Sofía Cuenca et al.|Journal of the American College of Cardiology|2016Cited by 472
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S. Maron, Theodore P. Abraham, Ahmad Masri et al.|New England Journal of Medicine|2024Cited by 277
Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids)Gabrielle Norrish, Juan Pablo Kaski, Tao Ding et al.|JAMA Cardiology|2019Cited by 248